Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a recombinant human IgGkappa monoclonal antibody that targets IL-17A and inhibits its interaction with the IL-17 receptor. Vunakizumab can be used to study autoimmune diseases such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis and inflammatory arthritis[1].
Molecular Weight:
(146.38 kDa)
Purity:
95.00
CAS Number:
[1792181-33-9]
Target:
Interleukin Related
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted